Manhattan Associates (MANH)
(Delayed Data from NSDQ)
$247.00 USD
0.00 (0.00%)
Updated Mar 18, 2024 04:00 PM ET
After-Market: $246.97 -0.03 (-0.01%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
MANH 247.00 0.00(0.00%)
Will MANH be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for MANH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MANH
SONY Reportedly Halts PlayStation VR2 Headset Production
NetApp (NTAP) Up 65% in the Past Year: Will the Rally Last?
MANH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Badger Meter (BMI) Rises 35% in a Year: Will the Rally Last?
EchoStar's (SATS) Hughes JUPITER System Deployed by RCSC
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar?
Other News for MANH
Definitive Healthcare had the biggest increase in short selling among software stocks - Baird
$1000 Invested In This Stock 20 Years Ago Would Be Worth $37,000 Today
Manhattan Associates initiated with neutral view at Citi, here's why
Cramer Says This Healthcare Stock Can Go Higher, Calls Manhattan Associates 'A Winner'
Looking Into Manhattan Associates's Recent Short Interest